Drug Trial Radar · NCT04464967
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Last checked: Nov 19, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 2021
Primary completion
Aug 2022
Study completion Feb 2023
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.
Conditions
- Advanced Solid Tumor
- Metastatic Cancer
- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER-2 Protein Overexpression
- Esophageal Cancer
- Ovarian Cancer
- Endometrium Cancer
- Bladder Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Non Small Cell Lung Cancer
- EGF-R Positive Non-Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Cervical Cancer
- Sarcoma
Interventions
SNK01Biological
Patient-specific ex vivo expanded autologous natural killer cells
TrastuzumabDrug
HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
CetuximabDrug
EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.Time frame: Up to 6 months
- Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.Time frame: Up to 6 months
- Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.Time frame: Up to 12 months
- Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.Time frame: Up to 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.